Syntagon to supply clinical material for Parkinson's research
Specialist Scandinavian contract research organisation, Syntagon, is to develop the lead compound for Phase I clinical trials carried out by A. Carlsson Research into Parkinson's disease, Huntington's disease and Brain Fatigue.
Specialist Scandinavian contract research organisation, Syntagon, is to develop the lead compound for Phase I clinical trials carried out by A. Carlsson Research into Parkinson's disease, Huntington's disease and Brain Fatigue.
In the first set of clinical trials, A. Carlsson Research will explore the effect of OSU 6162 on these diseases.
Arvid Carlsson, chief executive of A. Carlsson Research, won the Nobel Prize in Physiology or Medicine in 2000 for his discovery of dopamine's function as a neurotransmitter. His research resulted in the discovery that Parkinson's is caused by a lack of dopamine in certain parts of the brain.
"We had heard good reports about Syntagon within the Swedish community. They are technically excellent, fast-responding and an ideal partner for a company of our size," said Carlsson.
"We are immensely proud to be a part of this new phase of research into these three debilitating conditions," said John Cameron, European sales and marketing director of Syntagon.
With twin operations in Soedertaelje, Sweden, and Riga, Latvia, Syntagon specialises in synthetic preparation of small molecules under GMP manufacture.